동물의약품 시장 비즈니스 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Animal Drugs Market was valued at USD 46.3 billion in 2025 and is estimated to grow at a CAGR of 5.8% to reach USD 82.5 billion by 2035.

Market growth is driven by the rising prevalence of animal diseases, increasing focus on livestock productivity, and growing pet ownership worldwide. The market is witnessing strong momentum due to the humanization of pets, where owners increasingly demand advanced healthcare solutions like human medicine. This trend has significantly boosted the demand for specialized therapeutics, preventive care products, and chronic disease management drugs for companion animals. Additionally, the expansion of veterinary healthcare infrastructure and increasing awareness about animal welfare are further accelerating market growth. Governments and regulatory bodies are also playing a crucial role by supporting animal health initiatives and ensuring the availability of effective and safe pharmaceutical products.

The increasing adoption of advanced veterinary medicines, including biologics and vaccines, is reshaping the industry landscape. Biologics are gaining traction as they offer safer and more targeted treatment options, particularly for disease prevention in livestock and immunization in companion animals. Moreover, technological advancements such as AI-driven drug discovery, telemedicine platforms, and digital diagnostics are improving accessibility and efficiency in veterinary care. The rapid expansion of online veterinary pharmacies and retail distribution channels is further enhancing product availability, especially in emerging markets. However, challenges such as high development costs, stringent regulatory requirements, and potential adverse effects associated with certain drugs continue to impact market dynamics. Despite these challenges, continuous R&D investments and innovation are expected to create new growth opportunities in the coming years.

Based on product, the drugs segment generated USD 24.8 billion in 2025. This segment includes a wide range of pharmaceuticals such as anti-infectives, antiparasitic drugs, anti-inflammatory agents, and cardiovascular medications that are essential for treating and preventing diseases in both companion and livestock animals. The increasing incidence of bacterial infections, parasitic infestations, and chronic conditions in animals has significantly boosted demand for these drugs. Additionally, the development of advanced formulations and targeted therapies is enhancing treatment effectiveness and compliance. The growing emphasis on antimicrobial stewardship and responsible drug usage is also driving innovation within this segment, encouraging the development of safer and more sustainable treatment options.

The injectable segment held a leading position in the market in 2025 and is projected to experience robust growth at a CAGR of 5.6% during the forecast period. This segment includes medications delivered through intramuscular, subcutaneous, and intravenous administration methods. The injectable route is preferred because it allows for rapid onset of action, accurate dosing, and reliable therapeutic effects, making it particularly suitable for urgent care and acute medical conditions. Parenteral administration is widely utilized for vaccines, antibiotics, analgesics, and other critical medications that demand immediate bioavailability and consistent efficacy. Additionally, the injectable format supports controlled release formulations, biologics, and high-potency drugs that cannot be effectively delivered orally, further driving its adoption across hospitals, clinics, and emergency care settings.

North America Animal Drugs Market reached USD 19.2 billion in 2025, driven by a large livestock population, high pet ownership rates, and advanced veterinary healthcare infrastructure. The region benefits from strong regulatory support, increasing spending on animal healthcare, and continuous innovation in veterinary pharmaceuticals. The U.S. plays a key role due to its large cattle population and significant demand for meat and dairy products, which necessitate effective disease management solutions. Furthermore, rising expenditure on veterinary services and the growing adoption of preventive healthcare measures are contributing to sustained market growth in the region.

Key players operating in the Global Animal Drugs Market include Boehringer Ingelheim, Ceva Sante Animale, Dechra Pharmaceuticals, Elanco Animal Health, Merck & Co., Inc. (MSD Animal Health), Vetoquinol, Virbac, Zoetis, Phibro Animal Health, HIPRA, Norbrook, and Indian Immunologicals. These companies are actively expanding their product portfolios, strengthening their distribution networks, and investing in research and development to maintain their competitive edge. Companies in the Global Animal Drugs Market are adopting several strategic initiatives to strengthen their market position. A key approach is mergers and acquisitions, enabling firms to expand their product portfolios and geographic presence. Companies are also heavily investing in R&D to develop innovative drugs, biologics, and targeted therapies that address evolving animal health needs. Strategic collaborations and partnerships with research institutions and distributors are helping enhance market reach and technological capabilities. Additionally, firms are focusing on digital transformation, including AI-based drug discovery and e-commerce platforms, to improve accessibility and customer engagement. Expansion into emerging markets and strengthening supply chain networks are further supporting long-term growth and competitiveness in the industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Indication trends
  • 2.2.4 Animal type trends
  • 2.2.5 Route of administration trends
  • 2.2.6 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of animal diseases
    • 3.2.1.2 Growing focus on livestock productivity
    • 3.2.1.3 Surging demand for pet insurance policies
    • 3.2.1.4 Growing government initiatives and support towards animal welfare
    • 3.2.1.5 Intensified R&D activities driving advancements in veterinary medicine
    • 3.2.1.6 Expanding online veterinary pharmacies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse side effects and drug recalls
    • 3.2.2.2 High cost associated with animal drugs development
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of veterinary healthcare infrastructure in emerging markets
    • 3.2.3.2 Increasing adoption of preventive veterinary care
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Policy landscape
• 3.6 Product pipeline analysis (Driven by Primary Research)
• 3.7 Investor overview
• 3.8 Consumer behaviour trends (Driven by Primary Research)
• 3.9 Impact of AI on the market
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 Antiparasitic
  • 5.2.2 Anti-inflammatory
  • 5.2.3 Anti-infectives
  • 5.2.4 Corticosteroids
  • 5.2.5 Tranquilizers
  • 5.2.6 Cardiovascular drugs
  • 5.2.7 Gastrointestinal drugs
  • 5.2.8 Other drugs
• 5.3 Vaccines
  • 5.3.1 Modified live vaccines (MLV)
  • 5.3.2 Killed inactivated vaccines
  • 5.3.3 Recombinant vaccines
• 5.4 Medicated feed additives
  • 5.4.1 Antibiotics
  • 5.4.2 Vitamins
  • 5.4.3 Amino acids
  • 5.4.4 Enzymes
  • 5.4.5 Antioxidants
  • 5.4.6 Prebiotics and probiotics
  • 5.4.7 Minerals
  • 5.4.8 Other medicated feed additives

Chapter 6 Market Estimates and Forecast, By Animal Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Companion animals
  • 6.2.1 Dogs
  • 6.2.2 Cats
  • 6.2.3 Horses
  • 6.2.4 Other companion animals
• 6.3 Livestock animals
  • 6.3.1 Poultry
  • 6.3.2 Swine
  • 6.3.3 Cattle
  • 6.3.4 Fish
  • 6.3.5 Other livestock animals

Chapter 7 Market Estimates and Forecast, By Indication, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Dermatology
• 7.3 Cardiovascular diseases
• 7.4 Gastrointestinal diseases
• 7.5 Respiratory diseases
• 7.6 Other indications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Injectable
• 8.4 Topical
• 8.5 Other routes of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospital pharmacies
• 9.3 E-commerce
• 9.4 Retail pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Poland
  • 10.3.7 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Taiwan
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 GCC Countries
  • 10.6.3 Israel

Chapter 11 Company Profiles

• 11.1 Agrolabo S.p.A
• 11.2 Boehringer Ingelheim International
• 11.3 Ceva Sante Animale
• 11.4 Chanelle Pharma
• 11.5 Dechra Pharmaceuticals
• 11.6 Durvet Animal Health Products
• 11.7 Elanco Animal Health
• 11.8 Endovac Animal Health
• 11.9 HIPRA
• 11.10 Indian Immunologicals
• 11.11 Merck & Co., Inc.
• 11.12 Neogen Corporation
• 11.13 Norbrook
• 11.14 Vetoquinol
• 11.15 Virbac
• 11.16 Zagro
• 11.17 Zoetis